↓ Skip to main content

Rivaroxaban-Induced Hemorrhage Associated with ABCB1 Genetic Defect

Overview of attention for article published in Frontiers in Pharmacology, December 2016
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter
2 X users

Citations

dimensions_citation
53 Dimensions

Readers on

mendeley
42 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Rivaroxaban-Induced Hemorrhage Associated with ABCB1 Genetic Defect
Published in
Frontiers in Pharmacology, December 2016
DOI 10.3389/fphar.2016.00494
Pubmed ID
Authors

Kuntheavy Ing Lorenzini, Youssef Daali, Pierre Fontana, Jules Desmeules, Caroline Samer

Abstract

We report a patient who presented a non-ST segment elevation myocardial infarction in the context of severe normocytic hypochromic anemia related to gastrointestinal bleeding, 3 months after switching anticoagulant from the vitamin K antagonist acenocoumarol to the direct oral anticoagulant rivaroxaban. High levels of both anti-Xa activity and rivaroxaban plasma concentrations were measured despite rivaroxaban withdrawal, suggesting reduced elimination/drug clearance. Estimated half-life was 2-3 times longer than usually reported. The patient is a homozygous carrier of ABCB1 variant alleles, which could have participated to reduced elimination of rivaroxaban. Furthermore, CYP3A4/5 phenotyping showed moderately reduced enzyme activity. Drug-drug interaction with simvastatin may have contributed to decreased rivaroxaban elimination. Although in the present case moderate acute renal failure probably played a role, more clinical data are required to elucidate the impact of ABCB1 polymorphism on rivaroxaban pharmacokinetics and bleeding complications.

Timeline

Login to access the full chart related to this output.

If you don’t have an account, click here to discover Explorer

X Demographics

X Demographics

The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
As of 1 July 2024, you may notice a temporary increase in the numbers of X profiles with Unknown location. Click here to learn more.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 42 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Netherlands 1 2%
Unknown 41 98%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 8 19%
Researcher 6 14%
Student > Doctoral Student 3 7%
Student > Postgraduate 3 7%
Student > Master 3 7%
Other 5 12%
Unknown 14 33%
Readers by discipline Count As %
Pharmacology, Toxicology and Pharmaceutical Science 10 24%
Medicine and Dentistry 8 19%
Social Sciences 2 5%
Agricultural and Biological Sciences 1 2%
Veterinary Science and Veterinary Medicine 1 2%
Other 2 5%
Unknown 18 43%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 23 July 2019.
All research outputs
#18,493,111
of 22,914,829 outputs
Outputs from Frontiers in Pharmacology
#8,302
of 16,206 outputs
Outputs of similar age
#309,973
of 420,355 outputs
Outputs of similar age from Frontiers in Pharmacology
#84
of 153 outputs
Altmetric has tracked 22,914,829 research outputs across all sources so far. This one is in the 11th percentile – i.e., 11% of other outputs scored the same or lower than it.
So far Altmetric has tracked 16,206 research outputs from this source. They receive a mean Attention Score of 5.0. This one is in the 37th percentile – i.e., 37% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 420,355 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 15th percentile – i.e., 15% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 153 others from the same source and published within six weeks on either side of this one. This one is in the 39th percentile – i.e., 39% of its contemporaries scored the same or lower than it.